{"Clinical Trial ID": "NCT00041067", "Intervention": ["INTERVENTION 1:", "Trastuzumab, Docetaxel, Vinorelbine and Filgrastim", "Trastuzumab, docetaxel, vinorelbine and filgrastim", "Docetaxel: 60 mg/m2 at day 1 of 21-day cycles", "Vinorelbine: 27.5 mg/m2 on days 8 and 15", "- filgrastim: 5 microg/kg/day on days 2 to 21", "Trastuzumab: 4 mg/kg per IV over a period of 90 minutes on day 1 of the first cycle, then 2 mg/kg per IV over a period of 30 minutes"], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "\u2022 Histologically confirmed breast cancer at stage IV", "ipsilateral supraclavicular lymph node metastasis", "HER2-positive by fluorescence in situ hybridization (FISH) or immunohistochemistry 3+ confirmed colouring in adjuvant or metastatic setting", "No exfoliations or ascites as the only disease sites", "No primary or metastatic tumours of the brain or central nervous system", "- Hormonal receptor status:", "Unspecified", "CHARACTERISTICS OF PATIENTS:", "Age:", "- 18 years and over", "Gender:", "Women", "Status of menopause:", "Unspecified", "Status:", "- Zubrod 0-2", "Life expectancy:", "Unspecified", "Haematopoietic:", "Absolute number of neutrophils at least 1500/mm^3", "Number of platelets of at least 100 000/mm^3", "Hepatic:", "Normal Bilirubine", "Aspartate aminotransferase or Alanine aminotransferase not exceeding 1.5 times the upper limit of normal (ULN)", "ALKALINE phosphatase not more than 2.5 times LSN", "- Renal:", "Unspecified", "Cardiovascular disorders:", "A normal left ventricular ejection fraction by multigated radionuclide angiography or echocardiogram (patients who have previously received anthracycline)", "No clinical evidence or history of cardiomyopathy", "Other:", "No pre-existing motor or sensory peripheral neuropathy of grade 2 or higher, except cancer abnormalities", "No previous severe hypersensitivity reactions to docetaxel or other medicinal products formulated with Polysorbate 80", "No other malignancy in the last 5 years, except for properly treated basal cell or squamous cell skin cancer, in situ cervix carcinoma or other properly treated stage I or II cancer, currently in full remission", "No known sensitivity to E. coli-derived proteins", "No pregnancy or breast-feeding", "Negative pregnancy test", "Fertile patients should use effective contraception", "THERAPE PRIOR CONCURENT:", "Biological therapy:", "Unspecified", "- Chemotherapy:", "At least 6 months after previous chemotherapy", "Previous anthracycline as an authorized adjuvant treatment", "No previous cumulative dose of doxorubicin greater than 360 mg/m2", "No previous cumulative dose of epirubicin greater than 720 mg/m^2", "No more than one previous treatment of adjuvant or neoadjuvant chemotherapy for a primary disease", "No previous docetaxel", "No anterior vinorelbine", "Previous authorised paclitaxel", "Endocrinotherapy:", "\u2022 Prior hormonal treatment as adjuvant therapy or for metastatic breast cancer is permitted", "No concomitant hormonal treatment", "Radiotherapy:", "At least 3 weeks since previous radiation therapy", "Surgery:", "At least 2 weeks since the previous operation and recovered"], "Results": ["Performance measures:", "1-year survival", "[Unspecified]", "Time limit: 1 year", "Results 1:", "Title of the arm/group: Trastuzumab, Docetaxel, Vinorelbine and Filgrastim", "Description of the arm/group: Trastuzumab, docetaxel, vinorelbine and filgrastim", "Docetaxel: 60 mg/m2 at day 1 of 21-day cycles", "Vinorelbine: 27.5 mg/m2 on days 8 and 15", "- filgrastim: 5 microg/kg/day on days 2 to 21", "Trastuzumab: 4 mg/kg per IV over a period of 90 minutes on day 1 of the first cycle, then 2 mg/kg per IV over a period of 30 minutes", "Total number of participants analysed: 74", "Type of measurement: Number", "Unit of measure: percentage of patients 93 (84 to 97)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0.73 (0.00 per cent)"]}